A novel targeting modality for renal cell carcinoma: Human osteocalcin promoter-mediated gene therapy synergistically induced by vitamin C and vitamin D3

Journal of Gene Medicine

Volumn 12, Issue 11, 2010, Pages 892-903

  Johnson, Nicole A ^a   Chen, Bing Hung ^d   Sung, Shian Ying ^b,c   Liao, Chia Hui ^b   Hsiao, Wan Chi ^b   W K Chung, Leland ^a,e   Hsieh, Chia Ling ^b,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Adenoviral vectors; Gene therapy; Osteocalcin promoter; Renal cell carcinoma; Vitamin C; Vitamin D3

Indexed keywords

ASCORBIC ACID; COLECALCIFEROL DERIVATIVE; CONDITIONALLY REPLICATING ADENOVIRUS; HYDROGEN PEROXIDE; MESSENGER RNA; OSTEOCALCIN; RO 259022; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; EPITHELIUM CELL; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SINGLE DRUG DOSE; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; ASCORBIC ACID; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; GENE THERAPY; GENETIC VECTORS; HUMANS; KIDNEY NEOPLASMS; MALE; MICE; MICE, KNOCKOUT; MICE, NUDE; OSTEOCALCIN; PROMOTER REGIONS, GENETIC; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; VITAMIN D; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MURINAE; MUS;

EID: 78649527524     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1516     Document Type: Article

References (68)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
3. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335: 865-875.
4. Janzen NK, Kim HL, Figlin RA, et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003; 30: 843-852.
5. Campbell SC, Flanigan RC, Clark JI. Nephrectomy in metastatic renal cell carcinoma. Curr Treat Options Oncol 2003; 4: 363-372.
6. Brower V. Cancer gene therapy steadily advances. J Natl Cancer Inst 2008; 100: 1276-1278.
7. Shirakawa T. The current status of adenovirus-based cancer gene therapy. Mol Cells 2008; 25: 462-466.
8. Sadeghi H, Hitt MM. Transcriptionally targeted adenovirus vectors. Curr Gene Ther 2005; 5: 411-427.
9. Huang P, Kaku H, Chen J, et al. Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and IL-2 in a mouse model of renal cell carcinoma. Cancer Gene Ther 2010; 17: 484-491.
10. Ou YC, Gardner TA, Kao C, et al. A potential for tissue restrictive gene therapy in renal cell carcinoma using MN/CA IX promoter. Anticancer Res 2005; 25: 881-886.
11. Haviv YS, van Houdt WJ, Lu B, et al. Transcriptional targeting in renal cancer cell lines via the human CXCR4 promoter. Mol Cancer Ther 2004; 3: 687-691.
12. Lian JB, Stein GS, Stein JL, et al. Osteocalcin gene promoter: unlocking the secrets for regulation of osteoblast growth and differentiation. J Cell Biochem Suppl 1998; 30/31: 62-72.
13. Ducy P, Karsenty G. Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene. Mol Cell Biol 1995; 15: 1858-1869.
14. Xiao G, Cui Y, Ducy P, et al. Ascorbic acid-dependent activation of the osteocalcin promoter in MC3T3-E1 preosteoblasts: requirement for collagen matrix synthesis and the presence of an intact OSE2 sequence. Mol Endocrinol 1997; 11: 1103-1113.
15. Franceschi RT, Iyer BS, Cui Y. Effects of ascorbic acid on collagen matrix formation and osteoblast differentiation in murine MC3T3-E1 cells. J Bone Miner Res 1994; 9: 843-854.
16. Lian JB, Stein GS, Stein JL, et al. Regulated expression of the bone-specific osteocalcin gene by vitamins and hormones. Vitam Horm 1999; 55: 443-509.
17. Sneddon WB, Bogado CE, Kiernan MS, et al. DNA sequences downstream from the vitamin D response element of the rat osteocalcin gene are required for ligand-dependent transactivation. Mol Endocrinol 1997; 11: 210-217.
18. Clemens TL, Tang H, Maeda S, et al. Analysis of osteocalcin expression in transgenic mice reveals a species difference in vitamin D regulation of mouse and human osteocalcin genes. J Bone Miner Res 1997; 12: 1570-1576.
19. Morrison NA, Shine J, Fragonas JC, et al. 1, 25-dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene. Science 1989; 246: 1158-1161.
20. Ko SC, Cheon J, Kao C, et al. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. Cancer Res 1996; 56: 4614-4619.
21. Koeneman KS, Kao C, Ko SC, et al. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J Urol 2000; 18: 102-110.
22. Hou Z, Nguyen Q, Frenkel B, et al. Osteoblast-specific gene expression after transplantation of marrow cells: implications for skeletal gene therapy. Proc Natl Acad Sci USA 1999; 96: 7294-7299.
23. Lian JB, Stein GS, Stein JL, et al. Marrow transplantation and targeted gene therapy to the skeleton. Clin Orthop Relat Res 2000; 379: S146-S155.
24. Shirakawa T, Terao S, Hinata N, et al. Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer. Hum Gene Ther 2007; 18: 1225-1232.
25. Hsieh CL, Gardner TA, Miao L, et al. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells. Cancer Gene Ther 2004; 11: 148-155.
26. Kubo H, Gardner TA, Wada Y, et al. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 2003; 14: 227-241.
27. Matsubara S, Wada Y, Gardner TA, et al. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res 2001; 61: 6012-6019.
28. Yeung F, Law WK, Yeh CH, et al. Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J Biol Chem 2002; 277: 2468-2476.
29. Hsieh CL, Yang L, Miao L, et al. A novel targeting modality to enhance adenoviral replication by vitamin D (3) in androgen-independent human prostate cancer cells and tumors. Cancer Res 2002; 62: 3084-3092.
30. Zekri J, Ahmed N, Coleman RE, et al. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 2001; 19: 379-382.
31. Bisanz K, Yu J, Edlund M, et al. Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. Mol Ther 2005; 12: 634-643.
32. Ducy P, Zhang R, Geoffroy V, et al. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997; 89: 747-754.
33. 3, dexamethasone, and local growth factors in primary human osteoblasts. J Cell Biochem 2002; 86: 348-356.
34. 3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Exp Cell Res 2002; 274: 323-333.
35. Roomi MW, House D, Eckert-Maksic M, et al. Growth suppression of malignant leukemia cell line in vitro by ascorbic acid (vitamin C) and its derivatives. Cancer Lett 1998; 122: 93-99.
36. Leung PY, Miyashita K, Young M, et al. Cytotoxic effect of ascorbate and its derivatives on cultured malignant and nonmalignant cell lines. Anticancer Res 1993; 13: 475-480.
37. Fang Q, Naidu KA, Zhao H, et al. Ascorbyl stearate inhibits cell proliferation and tumor growth in human ovarian carcinoma cells by targeting the PI3K/AKT pathway. Anticancer Res 2006; 26: 203-209.
38. Harris DT. Hormonal therapy and chemotherapy of renal-cell carcinoma. Semin Oncol 1983; 10: 422-430.
39. Fabian MA, Biggs WH III, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005; 23: 329-336.
40. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
41. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
42. Wysocki PJ mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. Expert Rev Mol Diagn 2009; 9: 231-241.
43. Dasanu CA, Clark BA III, Alexandrescu DT. mTOR-blocking agents in advanced renal cancer: an emerging therapeutic option. Expert Opin Investig Drugs 2009; 18: 175-187.
44. Hudes GR. Targeting mTOR in renal cell carcinoma. Cancer 2009; 115: 2313-2320.
45. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
46. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456.
47. Oudard S, Medioni J, Aylllon J, et al. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2009; 9: 705-717.
48. Sharma A, Tandon M, Bangari DS, et al. Adenoviral vector-based strategies for cancer therapy. Curr Drug Ther 2009; 4: 117-138.
49. Karami S, Brennan P, Rosenberg PS, et al. Analysis of SNPs and haplotypes in vitamin D pathway genes and renal cancer risk. PLoS One 2009; 4: e7013.
50. Karami S, Brennan P, Hung RJ, et al. Vitamin D receptor polymorphisms and renal cancer risk in Central and Eastern Europe. J Toxicol Environ Health A 2008; 71: 367-372.
51. Byrne IM, Flanagan L, Tenniswood MP, et al. Identification of a hormone-responsive promoter immediately upstream of exon 1c in the human vitamin D receptor gene. Endocrinology 2000; 141: 2829-2836.
52. Boyan BD, Schwartz Z. Rapid vitamin D-dependent PKC signaling shares features with estrogen-dependent PKC signaling in cartilage and bone. Steroids 2004; 69: 591-597.
53. 3-dependent upregulation of the rat osteocalcin (OC) gene expression in osteoblastic cells. J Steroid Biochem Mol Biol 2004; 89/90: 269-271.
54. Carosio R, Zuccari G, Orienti I, et al. Sodium ascorbate induces apoptosis in neuroblastoma cell lines by interfering with iron uptake. Mol Cancer 2007; 6: 55.
55. Kang JS, Cho D, Kim YI, et al. Sodium ascorbate (vitamin C) induces apoptosis in melanoma cells via the down-regulation of transferrin receptor dependent iron uptake. J Cell Physiol 2005; 204: 192-197.
56. Lin SY, Lai WW, Chou CC, et al. Sodium ascorbate inhibits growth via the induction of cell cycle arrest and apoptosis in human malignant melanoma A372 cells. Melanoma Res 2006; 16: 509-519.
57. 2+ signal in the ascorbate-induced apoptosis in a human hepatoma cell line. Arch Pharm Res 2004; 27: 1245-1252.
58. Hong SW, Jin DH, Hahm ES, et al. Ascorbate (vitamin C) induces cell death through the apoptosis-inducing factor in human breast cancer cells. Oncol Rep 2007; 18: 811-815.
59. Du J, Martin SM, Levine M, et al. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res 2010; 16: 509-520.
60. Oberley TD, Oberley LW. Antioxidant enzyme levels in cancer. Histol Histopathol 1997; 12: 525-535.
61. Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 2005; 102: 13604-13609.
62. Mikirova NA, Ichim TE, Riordan NH. Anti-angiogenic effect of high doses of ascorbic acid. J Transl Med 2008; 6: 50.
63. Hinata N, Shirakawa T, Terao S, et al. Progress report on phase I/II clinical trial of Ad-OC-TK plus VAL therapy for metastatic or locally recurrent prostate cancer: initial experience at Kobe University. Int J Urol 2006; 13: 834-837.
64. Hoffer LJ, Levine M, Assouline S, et al. Phase I clinical trial of iv. ascorbic acid in advanced malignancy. Ann Oncol 2008; 19: 1969-1974.
65. Padayatty SJ, Riordan HD, Hewitt SM, et al. Intravenously administered vitamin C as cancer therapy: three cases. CMAJ 2006; 174: 937-942.
66. Riordan HD, Riordan NH, Jackson JA, et al. Intravenous vitamin C as a chemotherapy agent: a report on clinical cases. PR Health Sci J 2004; 23: 115-118.
67. Lappe JM, Travers-Gustafson D, Davies KM, et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007; 85: 1586-1591.
68. Schwartz GG. Vitamin D and intervention trials in prostate cancer: from theory to therapy. Ann Epidemiol 2009; 19: 96-102.